Related Experiment Video
Updated: Nov 6, 2025

11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
39.2K
Apremilast for immune checkpoint inhibitor-induced psoriasis: A case series
Ander Mayor Ibarguren1, Espinosa Arranz Enrique2, Peiteado Lopez Diana3
1Department of Dermatology, Hospital Universitario La Paz, Madrid, Spain.
JAAD Case Reports
|May 5, 2021
Abstract
No abstract available in PubMed .
Keywords:
BSA, body surface areaICI, immune checkpoint inhibitorPASI, psoriasis area severity indexPD-1, programmed cell death protein 1PDE-4 inhibitorsPDL-1, programmed death-ligand 1PFS, progression free survivalPGA, physician's global assessmentanti-pd1apremilastimmune checkpoint inhibitorsimmune-induced psoriasisimmune-related adverse eventsirAE, immune-related adverse eventsnivolumabpSA, psoriatic arthritispsoriasissupportive dermato-oncologyRelated Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
300
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
300
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
304
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
304
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.4K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.4K
Asthma: Pathogenesis and Management
909
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
909
Antiasthma Drugs: Leukotriene Modifiers
1.4K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.4K
